News Snapshot:
In December last year, the Chinese NMPA approved amubarvimab/romlusevimab combination for Covid-19. Credit: NIAID / Flickr (Creative Commons). TSB Therapeutics, a joint venture (JV) majority-owned by Brii Biosciences (Brii Bio), has entered a collaboration with China Resources Pharmaceutical Commercial Group (CR Pharma) for the commercialisation of an antibody therapy,… Read More… Source: https://www.pharmaceutical-technology.com/news/tsb-cr-pharma-covid-antibody/
